Salvage treatment with apatinib for advanced non-small-cell lung cancer

OBJECTIVE: No definitive chemotherapeutic regimen has been established in patients with non-small-cell lung cancer (NSCLC) who failed second- or third-line treatment. The aim of this study was to evaluate apatinib, a VEGFR-2 inhibitor, in advanced NSCLC as salvage treatment. METHODS: We evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zhengbo, Yu, Xinmin, Lou, Guangyuan, Shi, Xun, Zhang, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370069/
https://www.ncbi.nlm.nih.gov/pubmed/28367065
http://dx.doi.org/10.2147/OTT.S113435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370069/
https://www.ncbi.nlm.nih.gov/pubmed/28367065
http://dx.doi.org/10.2147/OTT.S113435

Ejemplares similares